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diagnosed and a strong relationship was demonstrated between neuropathic pain
and HRQL.
PND61
QUALITY OF LIFE OF SPANISH FAMILY CARERS IN HUNTINGTON’S DISEASE
Urbinati D1, Dorey J2, Trigo P3, Yebenes J3, Toumi M4
1Creativ-Ceutical, Luxembourg, Luxembourg, 2Creativ Ceutical, Paris, France, 3Hospital Ramón y
Cajal, Madrid, Spain, 4University Claude Bernard Lyon 1, Lyon, France
OBJECTIVES: Huntington’s disease (HD) is a rare neurodegenerative disease lead-
ing to sustained disability for patients, and poor quality of life (QoL) for patients and
their caregivers. This study, conducted in Spain as a part of an international survey,
investigated the QoL of family carers of patients with HD. METHODS: The hospital
‘Hospital Ramon y Cajal’ provided their patients with two self-reported question-
naires (one for patient and one for his/her caregiver). Caregivers were asked to
answer sociodemographic questions and complete the short version of the HD
Quality of Life Battery for Carers (HDQoL-C), a previously validated questionnaire
by Aubeeluck A. and Buchanan H. The determinants of caregiver QoL relating to
patients’ clinical characteristics (motor, functional, behavioural disorders) were
studied by regression analysis, adjusting for age, sex and occupational categories.
The relationship between QoL of patients and caregivers was also explored using
Pearson’s correlations. RESULTS: Sixty caregivers and 59 patients were included.
The mean ( standard deviation; SD) age of caregivers was 49 (14) years and 73%
were female. 10% were completely unsatisfied with their overall QoL and 12% were
totally satisfied. Patients’ motor score and functional score were found to be drivers
of the Spanish caregivers’ QoL (p0.02, for both) but the behavioral score was not
(p0.18). The caregiver total QoL score was not significantly correlated with pa-
tients EQ-5D index score (p0.11) and HD-specific QOL assessment, H-QOL-I
(p0.36). CONCLUSIONS: Caregiver’s QoL worsens as patient motors’ symptoms
and functional capacity deteriorate. Patient and caregiver QoL was not directly
correlated. A limitation of this study is the low sample size; HD is a rare disease,
which made it difficult to recruit large sample.
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OBJECTIVES: The quality of life (QoL) of informal caregivers can be adversely af-
fected by a number of factors. This issue, however, has not been well explored for
carers of people with Parkinson’s disease (PD). This study aims to determine the
main influences on carer QoL in this population. METHODS: Carers completed the
PDQ-Carer, a 29 item instrument incorporating four dimensions (Social and Per-
sonal Activities, Anxiety and Depression, Self-Care and Stress). PWP completed the
PDQ-39, a 39 item instrument containing eight dimensions (Mobility, Activities of
Daily Living, Emotional Well-Being, Stigma, Social Support, Cognitions, Communi-
cation and Bodily Discomfort). Regression analyses were performed to identify
factors related to carer QoL. RESULTS: The sample comprised 238 carers (mean age
68.20 years) and 238 PWP (mean age 71.64). The mean duration of caring was 8.13
years. Carer Social and Personal Activities were significantly related to caregiver
age (p 0.01), PWP Mobility (p 0.01) and Cognitions (p 0.01). Carer Anxiety and
Depression were significantly related to caregiver age (p  0.01), length of caregiv-
ing (p  0.05), PWP Emotional Well-Being (p  0.05), Cognitions (p  0.01) and
Communication (p  0.05). Caregiver Self-Care was significantly related to care-
giver age (p  0.05), length of caregiving (p  0.05), PWP Mobility (p  0.01), Emo-
tional well-being (p  0.05) and Cognitions (p  0.05). Caregiver Stress was signifi-
cantly related to caregiver age (p  0.05), length of caregiving (p  0.01) and PWP
Cognitions (p 0.01). CONCLUSIONS: Results suggest multiple influences on care-
giver QoL. Carer age and length of time in the caregiving role appear to be of
particular importance, as do PWP levels of mobility and cognitive impairment.
Practitioners and service providers should be aware of the heightened impact of PD
on carers over time and also as PWP symptoms deteriorate.
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OBJECTIVES: To report the impact of BG-12 (dimethyl fumarate) on patient health-
related quality of life (HRQoL) in DEFINE, a 2-year, randomized, double-blind, pla-
cebo-controlled, multicentre study of the efficacy and safety of BG-12 in patients
with relapsing–remitting multiple sclerosis (RRMS). METHODS: Patients aged
18–55 years with RRMS (McDonald criteria) and an Expanded Disability Status Scale
(EDSS) score of 0–5.0 were randomized 1:1:1 to placebo or oral BG-12 240 mg twice
(BID) or three times daily (TID). A Short Form (SF)-36 questionnaire was adminis-
tered to assess health status and HRQoL on 8 multi-item 100-point scales at base-
line, 24 weeks, 1 year and 2 years; higher scores indicated better HRQoL. These
scores were used to calculate the Physical Component Summary (PCS) and Mental
Component Summary (MCS) scores. RESULTS: Overall, 1,234 patients were en-
rolled and treated. Mean baseline PCS and MCS scores decreased with increasing
disability (EDSS score). Mean SF-36 PCS scores increased from baseline to 2 years
with BG-12 BID (0.45) and TID (0.51) versus a decrease with placebo (1.36; both
p0.001), indicating an improvement in physical health and well-being. Similar
trends were observed on SF-36 MCS scores (BG-12 BID [0.20] and TID [1.05]
versus placebo [1.06]; p0.065 and p0.002, respectively). Most individual do-
main scores revealed a significant treatment effect for BG-12 BID at 6, 12, and 24
months. The proportion of patients who achieved clinically important improve-
ments in PCS and MCS scores (5-point change) was significantly higher in the
BG-12 groups versus placebo (all p0.05). CONCLUSIONS: Together with the signif-
icant effects on clinical endpoints (reduced proportion of patients relapsed, annu-
alized relapse rate, and disability progression) and magnetic resonance imaging
measures of disease activity, the demonstrated benefits on patient-reported
HRQoL further supports a potential role for BG-12 as a valuable oral treatment
option in patients with relapsing MS.
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OBJECTIVES: Hereditary angioedema (HAE) due to C1-INH deficiency is a rare or-
phan disease characterised by spontaneous attacks of oedema that interrupt the
normal attack-free state. HAE is known to impact patient quality of life (QoL) and
productivity but, despite a recent increase in treatment options, there remains a
shortage of data to quantify these important aspects of the HAE disease. Sweha-
Reg, a population based census of HAE in Sweden, implemented a retrospective
patient survey to address this data gap and define the burden of HAE in Sweden.
METHODS: A retrospective registry study of Swedish patients with HAE (captured
by the Sweha-Reg census). Data was collected using a paper-based survey. Patients
completed EQ5D-5L questionnaires for attack-free and acute HAE attack states. To
be included in the analysis, patients must have suffered an attack in the last 12
months. Questions related to patient demographics (age and sex) and other param-
eters (such as attack location and severity) were included to better understand the
burden of HAE. EQ5D-5L values were estimated for both HAE disease states and
then compared with other variables; utilities were also calculated. Patient-reported
sick-leave was analysed to understand the factors responsible for productivity loss
in patients with HAE. RESULTS: A total of 105 valid responses were analysed from
an initial mailing of 139 surveys (76% response rate). 94% of patients reported an
attack in the last 12 months. The total number of attacks reported per patient
during one year ranged from 1 to 120. A significant reduction in QoL scores between
the attack-free and acute attack states of HAE was observed. Also, attack location
and severity had a clear impact on the utility values. CONCLUSIONS: Results from
this Sweha-Reg study provide an insight to the significant impact on QoL and
productivity loss that HAE has on patients in Sweden.
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OBJECTIVES: To assess the follow-up level of the recommended guidelines for the
treatment of Multiple Sclerosis (MS) developed by the Spanish Neurology Society
(SEN) for the treatment of patients with relapsing remitting MS (RRMS).METHODS:
Non-interventional, retrospective, and multicenter study that recruited patients
with RRMS and clinical evolution of at least 5 years. Four hundred patients in 40
different centers are expected to be recruited in the ongoing study. The primary
variable of the study (follow-up and monitoring of the SEN Guidelines for the man-
agement of MS patients) has been obtained by researchers’ ad-hoc questionnaire
that includes activities and evaluation criteria taken into account when a thera-
peutic change should be considered. These changes should be made when there is
a presence of an inadequate clinical response defined by one or more of the follow-
ing circumstances: the same or higher number of relapses than during the previous
year, 2 relapses/year, one relapse and one gadolinium enhancing lesion per year,
and/or increase of 1 sustained point for the last six months without relapses (0.5 if
EDSS  5.5 or 1.5 if EDSS  0). RESULTS: The study is currently finalizing the
inclusion of patients and the analyses are just being initiated. The FUTURA Study
will evaluate the circumstances that determine treatment choice, therapeutic
changes, and monitoring and control issues based on patient clinical history de-
tails, and if the decision to change treatment is made following the SEN guidelines
for the treatment of such patients. CONCLUSIONS: The FUTURA Study will assess
the follow-up and compliance of the Spanish Neurology Therapeutic MS Guidelines
recommendations for the treatment of RRMS patients by Spanish neurologists.
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